Epigral Limited (Epigral), India’s leading integrated chemical manufacturer, today announced its financial results for the quarter ended December 31, 2024. The company posted a robust PAT growth for Q3 FY25 at Rs. 104 crore, a jump of 110% as compared to Rs. 49 crore in Q3FY24. The quarterly revenue rose by 37% to Rs. 649 crore as against Rs. 474 crore recorded in Q3 FY24.

Commenting on the results, Maulik Patel, CMD, Epigral said: “Epigral’s revenue grew by 37% in nine months of FY2025 on account 15% growth in sales volume from Derivatives business and high value products. The diversification strategy of our company has played a key role in witnessing consistent and stable growth in this subdued demand scenario. Revenue contribution from Derivatives business stood at 54% for 9MFY25 vs 44% in 9MFY24”

“Epigral is a growth-focused company and the volume in FY 2025 grew on account of various projects commissioned in the recent past. These projects will further contribute in FY2026 along with a contribution from Chlorotoluenes Value Chain, it is expected to get commissioned in the current quarter. Further we are expanding and doubling our CPVC Resin and Epichlorohydrin capacity and we expect volume contribution from these projects from FY2027 onwards.

At Epigral we are moving in line with our strategy to grow consistently along with strengthening our integrated complex and catering to diversified industries for creating value for our stakeholders,” Patel added.